@inproceedings{inproceedings, title = {{52-week laboratory safety findings from an open-label extension (OLE) study of dupilumab in adolescent patients with atopic dermatitis (LIBERTY AD PED-OLE)}}, url = {{}}, year = {{2021}}, month = {{1}}, author = {{Cork MJ and Lockshin B and Blauvelt A and Chen Z and Khokhar FA and Bansal A and Prescilla R}}, volume = {{85}}, journal = {{JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY}}, issue = {{3}}, pages = {{AB120-AB120}}, note = {{Accessed on 2025/07/17}}}